Fig. 4: Overexpression of C-JUN restored anti-AML activity of CAR T cells.

A Schematic of CAR constructs (gemtuzumab ozogamicin, GO). B Schematic of mouse model. NSG mice received U937 cells intravenously followed by CAR T cells or control PCDH T cells 5 days later. C Representative bioluminescence imaging of mouse model after CAR T treatment, n = 2 in IL15-CAR T group, n = 3 in other groups. Survival curve (D) and quantification of tumor burden (E) as indicated by average radiance (p/sec/cm²/sr) of (C), n = 2 in IL15-CAR T group, n = 3 in other groups. F CAR T-cell counts in PB, data are summarized from two independent experiments, n = 3 in PCDH and IL15-CAR T group, n = 4 in LCK-CAR T and ZAP70-CAR T group, n = 5 in Control CAR T and C-JUN-CAR T group. G, J, M Representative bioluminescence imaging of mouse model after CAR T treatment, n = 3. H, K, N Quantification of (G, J, M) showing the tumor burden as indicated by average radiance (p/sec/cm²/sr), n = 3. (I, L, O) Survival curve of NSG mice in (G, J, M), n = 3. P Cytokine levels in tail blood collected on days 7, 14, and 21 post-infusion, n = 6. Q Pathological analysis of the heart, liver, spleen, lung, and kidney of the representative two mice in the control and C-JUN CAR T-treatment group at their terminal stage by using HE staining. Magnification, 200×. R Cytolytic activity of control and C-JUN CAR T cells against U937 cells in vitro, CAR T cells were sorted from the mice spleen, n = 3. For all bar plots, data are shown as mean ± SD. Assays were performed on day 10 after T-cell initial activation. Two-sided unpaired t-tests or multiple two-sided unpaired t tests were used to assess significance in (P, R). Survival curves were compared using the log-rank Mantel-Cox test in (D, I, L, O). All numbers defined by “n” indicate the number of biological replicates with different mice. Data are representative of two independent experiments. NS not significant. Source data are provided in the Source Data file.